Bridgebio Oncology Therapeutics, Stock Target Price
| BBOT Stock | 11.54 0.19 1.67% |
BridgeBio Oncology's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting BridgeBio Stock price.
BridgeBio | Target Price | Build AI portfolio with BridgeBio Stock |
BridgeBio Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BridgeBio Oncology's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BridgeBio Oncology could also be used in its relative valuation, which is a method of valuing BridgeBio Oncology by comparing valuation metrics of similar companies.BridgeBio Oncology is currently under evaluation in target price category among its peers.
BridgeBio Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BridgeBio Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BridgeBio Oncology's managers, analysts, and investors.Environmental | Governance | Social |
BridgeBio Fundamentals
| Current Valuation | 856.64 M | ||||
| Shares Outstanding | 79.2 M | ||||
| Shares Owned By Insiders | 24.04 % | ||||
| Shares Owned By Institutions | 51.02 % | ||||
| Number Of Shares Shorted | 976.87 K | ||||
| EBITDA | (80.66 M) | ||||
| Net Income | 7.6 M | ||||
| Total Debt | 5.71 M | ||||
| Book Value Per Share | (403.34) X | ||||
| Cash Flow From Operations | (763.82 K) | ||||
| Short Ratio | 2.07 X | ||||
| Earnings Per Share | (1.11) X | ||||
| Target Price | 24.2 | ||||
| Number Of Employees | 81 | ||||
| Market Capitalization | 1.01 B | ||||
| Total Asset | 194.42 M | ||||
| Retained Earnings | (3.73 M) | ||||
| Working Capital | 139.11 M | ||||
| Net Asset | 194.42 M |
About BridgeBio Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BridgeBio Oncology Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BridgeBio Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BridgeBio Oncology Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.